Q1 2026 Protalix Biotherapeutics Inc Earnings Call Transcript

May 13, 2026 / 12:00 PM GMT

Release Date Price: $1.93 (+1.05%)

Transcript 10-Q8-K

Key Points

Positve

Protalix BioTherapeutics Inc (PLX) received a $25 million milestone payment following the European Commission's approval of El Fabrio's every four weeks dosing regimen.
The company ended the first quarter with $51 million in cash, providing a strong balance sheet and substantial financial flexibility.
Protalix BioTherapeutics Inc (PLX) reaffirmed its 2026 revenue guidance, expecting total revenue to range from $78 million to $83 million.
The company is actively enrolling for the PRX-115 Phase II release study, with top-line results expected in the second half of 2027.
Protalix BioTherapeutics Inc (PLX) operates a profitable commercial business, with net income for the quarter at $18.3 million, compared to a net loss in the prior year period.

Negative

Revenues from selling goods decreased to $7.4 million from $10 million in the first quarter of 2025, reflecting lower purchases by Pfizer.
R&D expenses increased to $5.4 million, up from $3.5 million in the prior year period, driven by the PRX-115 Phase 2 release study.
SG&A expenses rose to $3.1 million, reflecting modest growth year-over-year, largely due to personnel-related costs.
The company has not provided specific updates on the progress of enrollment for the PRX-115 Phase II release study.
Initial data or insights into the market uptake of El Fabrio's every four weeks dosing regimen are not yet available, with expectations of seeing results in the second half of the year.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PLX.A - Protalix Biotherapeutics Inc
Q1 2026 Protalix Biotherapeutics Inc Earnings Call
May 13, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning, ladies and gentlemen, and welcome to the Protalix Biotherapeutics First Quarter 2026 Financial and Business Results Conference Call. As a reminder, this conference is being recorded. I will now turn the conference over to our host, Mr. Mike Moyer of Lifesci Advisors, Investor Relations for Protalix. Thank you. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and welcome to the Protalix Biotherapeutics Q1 2026 Financial Results and Business Update Conference Call. With me today are Drur Bachand, President and CEO of

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.